Skip to content

EFFICACY AND SAFETY OF MICROEMULSION SPRAY FROM REAUN MOOL NOK REMEDY IN PATIENTS WITH MILD CHRONIC PLAQUE PSORIASIS (CLINICAL TRIAL PHASE II)

EFFICACY AND SAFETY OF MICROEMULSION SPRAY FROM REAUN MOOL NOK REMEDY IN PATIENTS WITH MILD CHRONIC PLAQUE PSORIASIS (CLINICAL TRIAL PHASE II)

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
TCTR
Registry ID
TCTR20251201007
Enrollment
29
Registered
2025-12-01
Start date
2025-04-25
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mild chronic plaque psoriasis Mild chronic plaque psoriasis, Microemulsion, Reaun Mool Nok

Interventions

Microemulsion base,Herbal Extract
Placebo,Microemulsion spray from Reaun-Mool-Nok remedy

Sponsors

Department of Thai Traditional and Alternative Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Men or women at least years of age at time of screening. 2. Patient with mild chronic plaque psoriasis as defined by BSA not more than 5 and PASI at not more than 3 3. Subjects must be able to comply with the study protocol and can arrive whenever the research study period's appointments allow. 4. Subjects who are informed in detail about the research study and express continue interest in participating.

Exclusion criteria

Exclusion criteria: 1. Subjects who receive topical treatment within 2 weeks, phototherapy, systemic and biologics treatment within 3 months. 2. Forms of psoriasis other than mild chronic plaque-type. And psoriatic arthritis. 3. Pregnant or lactating women. If subjects are women who are able to become pregnant, it is expected that subjects will use an effective method of birth control for at least 15 days before the study. To confirm to the extent medically possible that subjects are not pregnant, subjects agree to have a pregnancy test done before beginning the study 4. Subjects with severe comorbidities such as significant liver and renal abnormalities. (Information from history taking) 5. Subjects who are allergic to ingredients with Reaun-Mool-Nok remedy. (Information from history taking) 6. Subjects with concurrent active psychological disorders such as psychosis, substance abuse, mood disorders or anxiety disorder. 7. Subjects who take medicine such as antihistamine and corticosteroids during the 2 weeks period before the study, which may obscure the treatment of the microemulsion spray from Reaun-Mool-Nok remedy extract. 8. Unreliable and poor compliance patient.

Design outcomes

Primary

MeasureTime frame
Local Psoriaisis Area And Severity Index Days 0, Week 2, Week 4, and Week 8 The Psoriaisis Area And Severity Index Local Score

Secondary

MeasureTime frame
Numerical Rating Scale Days 0, Week 2, Week 4, and Week 8 Numerical Rating Scale,Dermatology Life Quality Index Days 0, Week 2, Week 4, and Week 8 Dermatology Life Quality Index

Countries

Thailand

Contacts

Public ContactKoonlanat Punyanuwat

Thammasat University

koonlanat1705@gmail.com0822133940

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Apr 4, 2026